INS and Insulin resistance: Earlier trials with fucoidan have shown mixed results, with one study reporting no significant effect on insulin resistance or most cardiometabolic markers in obese, nondiabetic subjects, while another noted decreased diastolic BP and LDL cholesterol but increased insulin and worsened insulin resistance [95].